Clinical trials: Recurrence Hepatocellular Carcinoma
Hepatitis B, Cirrhosis
Prevention of Recurrent Hepatitis B After Liver Transplantation
Hepatitis B accounts for approximately 5000 deaths per year in the United States. Liver transplantation offers the only hope for patients who develop end-stage liver disease.
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT00059267
- Testing
- HBIG, Epivir, Hepsera
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatocellular Carcinoma
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
To evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma
- Trial name
- NCT05621499
- Testing
- HAIC, Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Transplant Disorder, Liver Cancer
Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Identifying patients at high risk for recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) represents a challenging issue.
- Conditions
- Liver Transplant Disorder, Liver Cancer, Recurrent Cancer
- Trial name
- TRAIN-AI (NCT05200195)
- Testing
- Liver transplantation
- Where
- Italy
- Volunteers
- 4,026 people
- Sponsor
- European Hepatocellular Cancer Liver Transplant Group
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
HepatoCellular Carcinoma
Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment
- Trial name
- SHOT (NCT03024684)
- Testing
- Atorvastatin
- Where
- 6 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- Chiayi Christian Hospital
HCC
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
ctDNA-based liquid biopsy can better detect the presence of MRD before imaging and serological markers, and is suitable for postoperative MRD and recurrence monitoring, which has been clinically validated in several cancer types…
- Trial name
- NCT05458115
- Testing
- Liver resection
- Volunteers
- 200 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Robotic Versus Laparoscopic Liver Resection for Hepatocellular Carcinoma
The objective of the study is to investigate the long-term outcomes of minimally invasive liver surgery (robotic vs laparoscopic) for hepatocellular carcinoma patients of stage BCLC 0-A.
- Trial name
- NCT06496113
- Testing
- Minimally invasive liver resection
- Volunteers
- 196 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Liver Cancer
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01011010
- Testing
- doxorubicin hydrochloride, mitomycin C, sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Recurrent Liver Carcinoma
Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
- Trial name
- NCT03008343
- Testing
- Irreversible Electroporation, Natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Oxaliplatin in Treating Patients With Liver Cancer
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have unresectable, recurrent or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00052364
- Testing
- oxaliplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
HCC Patients After Curative Treatment With Low HBV Viral Load
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence
Hepatocellular carcinoma(HCC) is prevalent in the hepatitis B virus(HBV) infection endemic areas. For early stage of HCC, surgical resection, radiofrequency ablation (RFA) or microwave ablation (MWA) are the main treatment…
- Trial name
- NCT04290936
- Testing
- Vemlidy® (Tenofovir Alafenamide; TAF)
- Where
- 4 sites in Taiwan
- Volunteers
- 402 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Liver Transplant
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
Liver transplantation not only removes the liver tumor (seed) but also eliminates the underlying diseased liver (soil), making it an essential therapeutic approach for hepatocellular carcinoma (HCC).
- Trial name
- NCT06409637
- Testing
- FOLFOX4 regimen, lenvatinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatitis C, Chronic
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
- Trial name
- NCT00375661
- Testing
- interferon-alfa-2b and ribavirin
- Where
- 2 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyoto University
Hepato Cellular Carcinoma (HCC)
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C)…
- Trial name
- NCT06812039
- Testing
- HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery
- Where
- 3 sites in China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence
Hepatectomy is still the most important treatment for HCC.High recurrence rate mostly influence it's prognosis, especially for the patient with tumor >5cm, multiple tumor and who cannot accept R0 resection.Our retrospective study…
- Trial name
- NCT00817895
- Testing
- sustained released 5-FU and sustained released cisplatin, sustained released 5-FU, TACE
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer
Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer
This is a phase I trial studying the side effects and best dose of stereotactic radiation therapy (SRT) in treating patients with advanced liver cancer.
- Trial name
- NCT00607828
- Testing
- stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Nebraska
Liver Transplantation, HCC
HOPE Against Cancer Recurrence in HCC
Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation.
- Conditions
- Liver Transplantation, HCC, Oncological Outcomes
- Trial name
- HOPE4Cancer (NCT06717919)
- Testing
- Hypothermic oxygenated perfusion, Conventional cold storage
- Where
- 37 sites in United States, Austria and 15 more
- Volunteers
- 220 people
- Sponsor
- Philipp Dutkowski
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
This phase II trial tests whether yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib work to shrink tumors in patients with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable) or…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT05327738
- Testing
- Atezolizumab, Biopsy, Cabozantinib S-malate
- Sponsor
- OHSU Knight Cancer Institute